| Inhibition of cancer antioxidant defense by natural compounds A Sznarkowska, A Kostecka, K Meller, KP Bielawski Oncotarget 8 (9), 15996, 2016 | 238 | 2016 |
| p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach? J Zawacka-Pankau, A Kostecka, A Sznarkowska, E Hedström, A Kawiak Cell Cycle 9 (4), 720-728, 2010 | 96 | 2010 |
| Comprehensive evaluation of the biological properties of surface-modified titanium alloy implants P Piszczek, A Radtke, M Ehlert, T Jędrzejewski, A Sznarkowska, ... Journal of clinical medicine 9 (2), 342, 2020 | 41 | 2020 |
| JNK–NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress A Kostecka, A Sznarkowska, K Meller, P Acedo, Y Shi, ... Cell death & disease 5 (10), e1484-e1484, 2014 | 38 | 2014 |
| Functional interfaces, biological pathways, and regulations of interferon-related DNA damage resistance signature (IRDS) genes M Padariya, A Sznarkowska, S Kote, M Gómez-Herranz, S Mikac, M Pilch, ... Biomolecules 11 (5), 622, 2021 | 32 | 2021 |
| Genetic variation in IL-10 influences the progression of hepatitis B infection M Rybicka, A Woziwodzka, A Sznarkowska, T Romanowski, P Stalke, ... International journal of infectious diseases 96, 260-265, 2020 | 25 | 2020 |
| MHC class I regulation: the origin perspective A Sznarkowska, S Mikac, M Pilch Cancers 12 (5), 1155, 2020 | 25 | 2020 |
| Pharmacological activation of tumor suppressor, wild-type p53 as a promising strategy to fight cancer A Sznarkowska, R Olszewski, J Zawacka-Pankau Postepy higieny i medycyny doswiadczalnej (Online) 64, 396-407, 2010 | 23 | 2010 |
| Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells A Sznarkowska, A Kostecka, A Kawiak, P Acedo, M Lion, A Inga, ... Cell Division 13, 1-12, 2018 | 22 | 2018 |
| Farmakologiczna aktywacja supresora nowotworu, natywnego białka p53 jako obiecująca strategia zwalczania nowotworów A Sznarkowska, R Olszewski, J Zawacka-Pankau Postępy Higieny i Medycyny Doświadczalnej 64, 2010 | 18 | 2010 |
| Targeting of p53 and its homolog p73 by protoporphyrin IX A Sznarkowska, K Maleńczyk, L Kadziński, KP Bielawski, B Banecki, ... FEBS letters 585 (1), 255-260, 2011 | 17 | 2011 |
| TNF‐α polymorphisms affect persistence and progression of HBV infection A Woziwodzka, M Rybicka, A Sznarkowska, T Romanowski, ... Molecular genetics & genomic medicine 7 (10), e00935, 2019 | 13 | 2019 |
| Identification of a stable, non-canonically regulated Nrf2 form in lung cancer cells S Mikac, M Rychłowski, A Dziadosz, A Szabelska-Beresewicz, ... Antioxidants 10 (5), 786, 2021 | 12 | 2021 |
| Viruses, cancer and non-self recognition M Padariya, U Kalathiya, S Mikac, K Dziubek, MC Tovar Fernandez, ... Open biology 11 (3), 200348, 2021 | 12 | 2021 |
| Liver cirrhosis in chronic hepatitis B patients is associated with genetic variations in DNA repair pathway genes M Rybicka, A Woziwodzka, A Sznarkowska, T Romanowski, P Stalke, ... Cancers 12 (11), 3295, 2020 | 11 | 2020 |
| Host genetic background affects the course of infection and treatment response in patients with chronic hepatitis B M Rybicka, A Woziwodzka, T Romanowski, A Sznarkowska, P Stalke, ... Journal of Clinical Virology 120, 1-5, 2019 | 8 | 2019 |
| Inhibition of Cancer Antioxidant Defense by Natural Compounds. Oncotarget, 8, 15996-16016 A Sznarkowska, A Kostecka, K Meller, KP Bielawski | 7 | 2017 |
| Functional interfaces, biological pathways, and regulations of interferon-related DNA damage resistance signature (IRDS) genes. Biomolecules 11, 622 M Padariya, A Sznarkowska, S Kote, M Gomez-Herranz, S Mikac, M Pilch, ... | 6 | 2021 |
| Inhibition of cancer antioxidant defense by natural compounds. Oncotarget 8 (9): 15996–16016 A Sznarkowska, A Kostecka, K Meller, KP Bielawski | 6 | 2017 |
| Inhibition of cancer antioxidant defense by natural compounds. Oncotarget, 2017, 8 (9), 15996-16016 A Sznarkowska, A Kostecka, K Meller, KP Bielawski | 6 | |